Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc.
By late June, Cara Therapeutics, Inc. (NASDAQ: CARA) stock had soared more than 175% year to date. Within a couple of weeks, however, many of those gains had been lost. Cara shares crashed after the biotech reported disappointing results from a phase 2 study of experimental pain drug CR845.
While the stock has climbed back somewhat, Cara is still well below the lofty levels of earlier in the summer. Can the comeback continue? I think so. Here's why the best is probably yet to come for Cara Therapeutics.
Image source: Getty Images.
Source: Fool.com
Cara Therapeutics Inc. Stock
Our community is currently high on Cara Therapeutics Inc. with 10 Buy predictions and 7 Sell predictions.
Based on the current price of 0.32 € the target price of 4 € shows a potential of 1139.93% for Cara Therapeutics Inc. which would more than double the current price.